Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
June 14, 2016 Capital Markets Day in New York City - Click here to view webcastservices.choruscall.com/links/mdxh160614
Exact +33%..Morgen de beurt aan MDXHealth? Waarom niet? Ze hebben lang genoeg met ons gesold, minstens zo lang als met Exact!
Harry... dan zullen wij morgen met zn allen moeten kopen... en meer dan dat. Dan kunnen we ook ff een shortsqueeze bewerkstelligen
Bij een + van 33% zitten we nog maar op €4. Om weer op de €5 te komen moeten we 65% stijgen.
vreemd vermogen schreef op 14 juni 2016 23:38 :
Bij een + van 33% zitten we nog maar op €4. Om weer op de €5 te komen moeten we 65% stijgen.
Dan maar 2 * 33% :-)
En we hebben er weer een licentie bij!!!
We moeten deze nieuwsflow nog een paar dagen doorzetten, dan moet er toch een stijging van de koers komen. Het mag ook wel met wat grote stappen. Die 33% zullen we niet snel zien denk ik, maar een paar keer 10+% mag wel hoor!!
Al dat nieuws moet volgens mij de koers van MDX toch eens laten knallen op termijn
beenhouwer schreef op 15 juni 2016 08:09 :
Al dat nieuws moet volgens mij de koers van MDX toch eens laten knallen op termijn
seekingalpha.com/article/2650065-mdxh... Met hartelijke dank van onze Inspirator.
Voorlopig liggen er alweer 5k laten op 3,05 en 5k op 3,10. Een slimme verkoper laat nu even niks zien en stapt weg nu er wat vraag te verwachten is. Waarom zo ver voor de opening die orders daar weer neerleggen? Heeft er toch echt de schijn van dat het blokkade orders zijn.
Een beetje informatie om de PR van deze morgen te duiden ivm die QIAsure Methylation Test waar MDXH een stukje toe bijdraagt: QIAGEN launches QIAsure Methylation Test to determine cervical cancer risk New follow-up assay helps stratify patients with transforming HPV infectionsHilden, Germany, and Salzburg, Austria, June 14, 2016 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAsure Methylation Test, a novel CE-marked molecular diagnostic test for use in differentiating patients’ risk of developing cervical cancer. The QIAsure Methylation Test is highly complementary to HPV screening tests and follows either a positive high risk HPV test or a finding of abnormal cells in cytology from a Pap smear and can be used on either clinician collected or self-collected samples. Currently available triage options such as HPV genotyping or tissue-based assays often have limited clinical value, or are subjective and in many cases lead to false positives or missed cervical disease. QIAsure testing accurately stratifies cervical cancer risk by detecting and measuring DNA methylation of two specific genes implicated in cervical cancer. In large scale studies, the DNA markers used in this assay have demonstrated reliable additional insights into a patient’s individual risk and contributed to decisions on surveillance and treatment. The test is being presented to the public for the first time at EUROGIN 2016, the international conference for the European Research Organization on Genital Infection and Neoplasia, in Salzburg, Austria. “QIAsure is a highly attractive and complementary addition to our leading HPV franchise”, said Thierry Bernard, Senior Vice President and Head of QIAGEN’s Molecular Diagnostics Business Area. “It creates a compelling solution for primary screening that includes the leading HPV primary screening test and leading solution for automated sample processing and molecular analysis of cervical samples.“ “The QIAsure Methylation Test is an important advance for women’s health. When a woman screens positive for HPV, or cytology shows abnormal cells, she is at risk of developing cervical cancer. The QIAsure test is the next logical step to assess this risk,” said Dr. Tadd Lazarus, Chief Medical Officer of QIAGEN. “This highly sensitive, specific molecular test identifies cancer specific epigenetic changes in cervical cells and enables the physician to assess whether the HPV infection is progressing toward cancer – a valuable insight that provides timely reassurance and guidance to treatment for each individual patient.” Medical need in cervical cancer detection Globally, cervical cancer affects approximately over 500,000 women annually and is the third-most-common malignancy in women after breast and colon cancer. Cervical cancer is caused by the human papillomavirus (HPV), and women can be screened for HPV – making the cancer highly preventable and treatable. The virus, however, is a common infection and in most cases HPV-infected cervical cells do not transform into cervical cancer. HPV testing is generally accepted as being more sensitive but less specific than cytology for detecting cervical disease. However, the benefit of increased disease detection using HPV as a primary test also results in many positive HPV tests in patients without underlying cervical disease. A positive HPV test result calls for follow-up testing to differentiate each patient’s risk based on cellular effects of the infection. With increased interest and uptake of HPV testing as a primary test, the need for a suitable triage test following a positive HPV test is increasing. QIAsure Methylation Test The CE-IVD marked QIAsure Methylation Test is launching in Europe, Middle East and Africa for use on either clinician-collected or self-collected specimens, a benefit for women and healthcare systems because self-sampling can streamline processes and avoid unnecessary further medical intervention. The test has been validated on the Rotor-Gene® Q MDx system, a PCR platform that is a member of the modular QIAsymphony family of automation solution. ... The QIAsure Methylation Test helps assess transforming HPV infections from non-threatening ones by detecting molecular changes known as methylation in promoter regions of host cell FAM19A4 and mir124-2 genes, which are hyper-methylated in cervical cancers. Current triage options are not ideal in stratifying risk: Genotyping of HPV16/18 lacks specificity, leading to false positive results; cytology lacks sensitivity, leading to missed cervical disease. By identifying hyper-methylation of these host cell genes, the QIAsure test provides highly sensitive and specific results for patients and clinicians. QIAsure will be available in Europe in the later course of 2016. About QIAGEN’s leadership in HPV testing QIAGEN is the global leader in providing highly reliable molecular tests for HPV screening, including the digene® HC2 HPV Test and the careHPV® Test for areas with limited resources. The new QIAsure Methylation Test perfectly adds to QIAGEN’s portfolio of diagnostic tools for use in women’s health and leverages the Company’s leading position in primary screening. QIAGEN’s digene® HC2 HPV Test, the Gold Standard for sensitive, early detection of high-risk HPV, has been evaluated in clinical trials involving more than 1 million women – and proven through 15 years of clinical practice and more than 90 million tests worldwide. The digene HPV test uses advanced Hybrid Capture 2 technology to directly detect the presence of 18 types of HPV and is the only HPV assay that examines the entire length of the genome, which helps prevent false negatives caused by gene deletions that occur naturally during a woman’s biological integration of the HPV virus. When the digene HPV Test rules out high-risk HPV, the result is highly reliable, based on the higher sensitivity of the HC2 technology. This benefit is seen to be of critical value in screening settings, in particular as intervals between screenings are extended as well as in primary screening settings. QIAGEN was the first company to implement large primary screening programs and has shown unrivalled validation and performance in doing so. The launch of QIAsure confirms QIAGEN’s commitment to market and technology leadership in the cervical cancer detection arena. About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research). As of March 31, 2016, QIAGEN employed approximately 4,600 people in over 35 locations worldwide. Further information can be found at www.qiagen.com.
is dit het nieuws waarop gewacht werd? nog even afwachten, want goed nieuws is niet altijd synoniem voor succes. Heb kleine positie genomen op 3.18
Niks is wat het lijkt schreef op 15 juni 2016 08:42 :
Voorlopig liggen er alweer 5k laten op 3,05 en 5k op 3,10. Een slimme verkoper laat nu even niks zien en stapt weg nu er wat vraag te verwachten is. Waarom zo ver voor de opening die orders daar weer neerleggen? Heeft er toch echt de schijn van dat het blokkade orders zijn.
Toch vreemd, nu zijn er weer orders aan de laatkant als sneeuw voor de zon verdwenen. Blijft schimmig allemaal.
Als die enorme stijging van Exas de voorloper zou zijn van een positieve evaluatie van Cologuard door USPSTF dan zal de verkoop van Cologuard - mede door die enorme PR-campagne van de laatste weken- enorm stijgen wat een zeer positieve invloed zal hebben op de royalties van MDXH . je moet wel zo blind zijn als een versleten mol om niet te zien welke enorme krachten zich hier bij MDXH onder de oppervlakte aan het opbouwen zijn. naar mijn heel bescheiden mening zijn er wel enkelen die dat al lang door hebben en die hun zaken met aandelen hebben volgestoken ten nadele en tot ergernis van menige twijfelaar.
Het is in ieder geval fijn dat er meer verschillende bronnen van inkomsten komen, zodat we niet afhankelijk zijn van een enkele of een paar bedrijven maar steady growing revenues krijgen.
Lekker vandaag alleen Harries en geen lords! Qiagen is een grote speler en weer een bron van inkomsten. Zoals Harry terecht opmerkt is de wagen meer dan volgeladen -:)
Ja ja dat gaat lekker zo bij Exas. Nou MDx 2x 33% en we staan op op €5,30 ( vanaf de 3) Het kan dus zomaar gebeuren.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
AIRBUS
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
Nextensa
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia Oyj
Nokia OYJ
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee